| For: | Fincham REA, Delvecchio FR, Goulart MR, Yeong JPS, Kocher HM. Natural killer cells in pancreatic cancer stroma. World J Gastroenterol 2021; 27(24): 3483-3501 [PMID: 34239264 DOI: 10.3748/wjg.v27.i24.3483] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i24/3483.htm |
| Number | Citing Articles |
| 1 |
Yu-Hsuan Hung, Li-Tzong Chen, Wen-Chun Hung. The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy. Biomedicines 2022; 10(4) doi: 10.3390/biomedicines10040926
|
| 2 |
Sung-Bae Kang, Ji Hye Jeong, Seung Wook Kim, Hyejin Yoo, Seunghun Lee, Ji-Hye Oh, Chang Ohk Sung, Seung-Hwan Lee, Eunsung Jun, Mihue Jang. Enhancing cancer killing and natural killer cell persistence by targeting NOXA, a predictor of poor patient survival. Molecular Therapy Oncology 2026; 34(1) doi: 10.1016/j.omton.2026.201152
|
| 3 |
Shuai Shao, Caroline N. Jones. Quantifying the Dual Effect of Antitumor and Pro-Tumor Human Neutrophils on Natural Killer Cell Behaviors in a Microphysiological System. ACS Biomaterials Science & Engineering 2026; 12(4) doi: 10.1021/acsbiomaterials.5c02083
|
| 4 |
Dong Dai, Sen Wang, Jiaze Li, Yu Zhao. Exploring radiation resistance-related genes in pancreatic cancer and their impact on patient prognosis and treatment. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1524798
|
| 5 |
Martina Cucchiara, Maria Teresa Palano, Cristian Rubuano, Gianluca De Antoni, Matteo Gallazzi, Daniele Mercatelli, Marta Tagliabue, Adelaide Pessi, Gianpiero Catalano, Maria Gemelli, Riccardo Ricotta, Pier Francesco Ferrucci, Gennaro Nappo, Silvia Uccella, Alessandro Zerbi, Patrizia Borsotti, Giulia Garattini, Federica Di Leva, Nicolò Baranzini, Annalisa Grimaldi, Lorenzo Mortara, Francesco Acquati, Paola Cornelia Muti, Dorina Belotti, Andrea Resovi, Barbara Bassani, Antonino Bruno. The TGF-βR1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization. Cell Death & Disease 2026; 17(1) doi: 10.1038/s41419-026-08581-9
|
| 6 |
Pancreatic Cancer: Basic Mechanisms and Therapies. Advances in Cancer Research 2023; 159 doi: 10.1016/bs.acr.2023.02.010
|
| 7 |
Tinghui Mao, Wenjiao Teng, Li Lin, Wei Zhou. Innate lymphoid cells in pancreatic ductal adenocarcinoma: Immune regulation and therapeutic implications. Cancer Letters 2025; 629 doi: 10.1016/j.canlet.2025.217890
|
| 8 |
Alexandra Bennion, Joanne Lysaght, Niamh Lynam‐Lennon. The insider's perspective: The intracellular complosome and immune cell dynamics in cancer. Clinical and Translational Medicine 2026; 16(2) doi: 10.1002/ctm2.70628
|
| 9 |
Hye-Seong Park, Jun Eul Hwang, Je-Jung Lee, Woo Kyun Bae. Synergistic Anti-Tumor Efficacy of Modified FOLFIRINOX and NK Cell Therapy in Pancreatic Ductal Adenocarcinoma. Cancers 2025; 17(17) doi: 10.3390/cancers17172785
|
| 10 |
Sara Fanijavadi, Mads Thomassen, Lars Henrik Jensen. Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy. International Journal of Molecular Sciences 2025; 26(2) doi: 10.3390/ijms26020515
|
| 11 |
|
| 12 |
Patrick V. Lawrence, Krisha Desai, Christopher Wadsworth, Nagina Mangal, Hemant M. Kocher, Nagy Habib, Anguraj Sadanandam, Mikael H. Sodergren. A Case Report on Longitudinal Collection of Tumour Biopsies for Gene Expression-Based Tumour Microenvironment Analysis from Pancreatic Cancer Patients Treated with Endoscopic Ultrasound Guided Radiofrequency Ablation. Current Oncology 2022; 29(10) doi: 10.3390/curroncol29100531
|
| 13 |
Christine S. Hughes, Oleg Blyuss, Hemant M. Kocher. Plasma vascular endothelial growth factor levels are a potential therapy-response biomarker for pancreatic cancer. Frontiers in Oncology 2026; 15 doi: 10.3389/fonc.2025.1672385
|
| 14 |
Duancheng Guo, Longyun Ye, Weiding Wu, Xianjun Yu, Kaizhou Jin. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer. Acta Biochimica et Biophysica Sinica 2023; 55(6) doi: 10.3724/abbs.2023045
|
| 15 |
Nicky A. Beelen, Merel R. Aberle, Virginia Bruno, Steven W. M. Olde Damink, Gerard M. J. Bos, Sander S. Rensen, Lotte Wieten. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1133796
|
| 16 |
Martina S. Lutz, Kevin Wang, Gundram Jung, Helmut R. Salih, Ilona Hagelstein. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1343929
|
| 17 |
Catarina Nascimento, Andreia Gameiro, Jorge Correia, João Ferreira, Fernando Ferreira. The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications. Cells 2022; 11(16) doi: 10.3390/cells11162578
|
| 18 |
Kawaljit Kaur. Role of Probiotics in Enhancing Immune Function and Improving the Effectiveness of Treatments for Pancreatic Cancer. Microorganisms 2025; 13(12) doi: 10.3390/microorganisms13122687
|
| 19 |
Fabian Kiehl, Nico De Lazzari, Ronja Beller, Isabella Deppe, Sabrina B. Bennstein, Suzan Botzenhardt, Maria Rosa Salvador Comino, Mitra Tewes, Miriam Götte. High‐Intensity Interval Training Boosts Immune Cells in Advanced Cancer Patients and Healthy Controls: Implications for Cancer Care. Cancer Medicine 2026; 15(6) doi: 10.1002/cam4.71977
|
| 20 |
Linhan Ye, Zongyao Chen, Jingcheng Zhang, Qiaolin Li. Modeling the Transitional Phase of Epithelial Cells Reveals Prognostic and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma. Cancers 2025; 17(11) doi: 10.3390/cancers17111813
|
| 21 |
Wei Liu, Dongwei Hu, Jinjie Li, Qigang Xu, Zongjing Chen, Bo Xu. CSTF2T facilitates pancreatic adenocarcinoma growth and metastasis by elevating H3K4Me1 methylation of CALB2 via ASH2L. Cancer Biology & Therapy 2023; 24(1) doi: 10.1080/15384047.2023.2216041
|
| 22 |
Hyun-Ah Kim, Hyunsoo Kim, Min-Kyung Nam, Jong Kook Park, Moo-Yeal Lee, Seok Chung, Kyung-Mi Lee, Hyo-Jeong Kuh. Suppression of the antitumoral activity of natural killer cells under indirect coculture with cancer-associated fibroblasts in a pancreatic TIME-on-chip model. Cancer Cell International 2023; 23(1) doi: 10.1186/s12935-023-03064-9
|
| 23 |
Beihan Dong, Yaoyun Zhang, Tingyue Kang, Fujun Wang, Gang Su. A new perspective for the diagnosis of pancreatic cancer: based on the understanding of extracellular vesicle proteins. Expert Review of Molecular Diagnostics 2025; 25(10) doi: 10.1080/14737159.2025.2545968
|
| 24 |
Peipei Wang, Congliang Chen, Kexin Lin, Yu Zhang, Junmei Hu, Tongbo Zhu, Xia Wang. The BCL2-associated athanogene-3–Interferon-induced transmembrane protein 2 axis enhances pancreatic ductal adenocarcinoma growth via the Mitogen-activated protein kinase signaling pathway. Carcinogenesis 2024; 45(12) doi: 10.1093/carcin/bgae053
|
| 25 |
Sofian Benkhaled, Cedric Peters, Nicolas Jullian, Tatjana Arsenijevic, Julie Navez, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem, Christelle Bouchart. Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?. Cancers 2023; 15(3) doi: 10.3390/cancers15030768
|
| 26 |
Virender Kumar, Ram I. Mahato. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles. Cancer Letters 2023; 579 doi: 10.1016/j.canlet.2023.216462
|
| 27 |
Zida Xu, Can Jin, Xuan Huang. Regulatory Networks of Non-Coding RNAs Modulating Natural Killer Cell Antitumor Immunity in the Tumor Microenvironment. Cells 2026; 15(14) doi: 10.3390/cells15141260
|
| 28 |
Qi Lu, Tian Liu, Zeyu Han, Jian Zhao, Xiaoyuan Fan, Helin Wang, Jiaxuan Song, Hao Ye, Jin Sun. Revolutionizing cancer treatment: The power of cell-based drug delivery systems. Journal of Controlled Release 2023; 361 doi: 10.1016/j.jconrel.2023.08.023
|
| 29 |
Greyson Biegert, Amanda Rosewell Shaw, Daisuke Morita, Caroline Porter, Ryu Matsumoto, Lisa Jatta, Noah Crooks, Mae Woods, Qizhi Cathy Yao, Robin Parihar, Masataka Suzuki. Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma. Molecular Therapy Oncology 2025; 33(2) doi: 10.1016/j.omton.2025.201006
|
| 30 |
Sara Fanijavadi, Lars Henrik Jensen. Dysbiosis–NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes. International Journal of Molecular Sciences 2025; 26(2) doi: 10.3390/ijms26020730
|
| 31 |
Camille Rolin, Gilles Iserentant, Aubin Pitiot, Carole Seguin-Devaux. Advanced Methodologies to Study and Enhance Cellular Cytotoxicity Against Cancer. Methods in Cell Biology 2026; 207 doi: 10.1016/bs.mcb.2026.04.001
|
| 32 |
Zhenglin Ou, Yebin Lu, Dayong Xu, Zhen Luo. Hypoxia mediates immune escape of pancreatic cancer cells by affecting miR-1275/AXIN2 in natural killer cells. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1271603
|